Lack of Improvement of Oral Absorption of ME3277 by Prodrug Formation Is Ascribed to the Intestinal Efflux Mediated by Breast Cancer Resistant Protein (BCRP/ABCG2)

No HeadingPurpose.ME3229, an ester-type prodrug of a hydrophilic glycoprotein IIb/IIIa antagonist (ME3277), failed to show improved oral absorption. Okudaira et al. (J. Pharmacol. Exp. Ther. 294. 580–587, 2000) provided a piece of evidence that this is ascribed to an efflux system, distinct from P-gp and MRP2, that extrudes ME3277 formed from ME3229 in the intestinal epithelial cells. The aim of the present study is to examine the involvement of breast cancer resistant protein (BCRP/ABCG2) as a cause of low oral absorption of ME3229.Methods.The transport activity of ME3277 in the presence and absence of ATP was determined using a rapid filtration method with the membrane vesicles prepared from LLC-PK1 cells expressing BCRP. The plasma concentrations of ME3229 and its metabolites were compared between Bcrp1−/− mice and wild-type mice after a single-pass perfusion of small intestine with ME3229.Results.The ATP-dependent uptake of ME3277 was greater in BCRP-expressing membrane vesicles than that in the control vesicles. Furthermore, it was found that after intestinal perfusion with ME3229 for 60 min, the plasma concentrations of ME3277 and PM-5, a metabolite of ME3229, increased 2-fold and 3-fold, respectively, in Bcrp1 knockout mice. It is possible that BCRP acts synergistically with intestinal carboxylesterases.Conclusion.These results suggest that Bcrp1 plays an important role in the intestinal efflux of ME3277 and, probably, PM-10 and PM-11, metabolites of ME3229, and limits its BA after oral administration of ME3229.

[1]  R. Loria,et al.  Measurement of intestinal absorption in mice by a double-label radioisotope perfusion technic. , 1976, Laboratory animal science.

[2]  P. Borst,et al.  Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[3]  M Hosokawa,et al.  The mammalian carboxylesterases: from molecules to functions. , 1998, Annual review of pharmacology and toxicology.

[4]  Y Zhang,et al.  Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[5]  D. Keppler,et al.  Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. , 1999, Biochimica et biophysica acta.

[6]  Y. Sugiyama,et al.  Polarized efflux of mono- and diacid metabolites of ME3229, an ester-type prodrug of a glycoprotein IIb/IIIa receptor antagonist, in rat small intestine. , 2000, The Journal of pharmacology and experimental therapeutics.

[7]  Y. Sugiyama,et al.  A study of the intestinal absorption of an ester-type prodrug, ME3229, in rats: active efflux transport as a cause of poor bioavailability of the active drug. , 2000, The Journal of pharmacology and experimental therapeutics.

[8]  J. Schellens,et al.  Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. , 2000, Journal of the National Cancer Institute.

[9]  Y. Sugiyama,et al.  Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[10]  H. Melhus,et al.  Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. , 2001, The Journal of pharmacology and experimental therapeutics.

[11]  H. Rosing,et al.  The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[12]  L. Doyle,et al.  Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) , 2003, Oncogene.

[13]  Jos H Beijnen,et al.  The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. , 2003, Cancer research.

[14]  Yuichi Sugiyama,et al.  ABCG2 Transports Sulfated Conjugates of Steroids and Xenobiotics* , 2003, Journal of Biological Chemistry.

[15]  L. Benet,et al.  Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. , 2003, Current drug metabolism.

[16]  Y. Sugiyama,et al.  Quantitative Evaluation of the Function of Small Intestinal P-Glycoprotein: Comparative Studies Between in Situ and in Vitro , 2003, Pharmaceutical Research.

[17]  H. Yuasa,et al.  Influence of Anesthetic Regimens on Intestinal Absorption in Rats , 1993, Pharmaceutical Research.

[18]  H. Kusuhara,et al.  Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[19]  Y. Sugiyama,et al.  Functional Analysis of SNPs Variants of BCRP/ABCG2 , 2004, Pharmaceutical Research.